130 related articles for article (PubMed ID: 28954884)
1. Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
Liewluck T
Neurology; 2017 Nov; 89(19):2017-2018. PubMed ID: 28954884
[No Abstract] [Full Text] [Related]
2. Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis.
Tawara N; Yamashita S; Zhang X; Korogi M; Zhang Z; Doki T; Matsuo Y; Nakane S; Maeda Y; Sugie K; Suzuki N; Aoki M; Ando Y
Ann Neurol; 2017 Apr; 81(4):512-525. PubMed ID: 28318044
[TBL] [Abstract][Full Text] [Related]
3. Reader response: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
Budhram A
Neurology; 2018 May; 90(21):990. PubMed ID: 29784723
[No Abstract] [Full Text] [Related]
4. Author response: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
Liewluck T
Neurology; 2018 May; 90(21):990. PubMed ID: 29784724
[No Abstract] [Full Text] [Related]
5. Positive Cytosolic 5-Nucleotidase 1A Antibodies in Motor Neuron Disease.
Assadi RK; Manousakis G
J Clin Neuromuscul Dis; 2020 Sep; 22(1):50-52. PubMed ID: 32833724
[TBL] [Abstract][Full Text] [Related]
6. Determination of cN1A Autoantibodies by Cell-Based Immunofluorescence Cytochemistry.
Yamashita S; Tawara N
Methods Mol Biol; 2019; 1901():89-94. PubMed ID: 30539570
[TBL] [Abstract][Full Text] [Related]
7. Cytoplasmic 5'-nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility.
Greenberg SA
Muscle Nerve; 2014 Oct; 50(4):488-92. PubMed ID: 24752512
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis.
Pluk H; van Hoeve BJ; van Dooren SH; Stammen-Vogelzangs J; van der Heijden A; Schelhaas HJ; Verbeek MM; Badrising UA; Arnardottir S; Gheorghe K; Lundberg IE; Boelens WC; van Engelen BG; Pruijn GJ
Ann Neurol; 2013 Mar; 73(3):397-407. PubMed ID: 23460448
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity and clinical utility of the anti-cytosolic 5'-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: Report of 40 patients from a single neuromuscular center.
Felice KJ; Whitaker CH; Wu Q; Larose DT; Shen G; Metzger AL; Barton RW
Neuromuscul Disord; 2018 Aug; 28(8):660-664. PubMed ID: 30001928
[TBL] [Abstract][Full Text] [Related]
10. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis.
Larman HB; Salajegheh M; Nazareno R; Lam T; Sauld J; Steen H; Kong SW; Pinkus JL; Amato AA; Elledge SJ; Greenberg SA
Ann Neurol; 2013 Mar; 73(3):408-18. PubMed ID: 23596012
[TBL] [Abstract][Full Text] [Related]
11. Anti-cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis.
Paul P; Liewluck T; Ernste FC; Mandrekar J; Milone M
Muscle Nerve; 2021 Apr; 63(4):490-496. PubMed ID: 33373040
[TBL] [Abstract][Full Text] [Related]
12. Significance of Sjögren's syndrome and anti-cN1A antibody in myositis patients.
Levy D; Nespola B; Giannini M; Felten R; Severac F; Varoquier C; Rinagel M; Korganow AS; Martin T; Poindron V; Maurier F; Chereih H; Bouldoires B; Hervier B; Lenormand C; Chatelus E; Geny B; Sibilia J; Arnaud L; Gottenberg JE; Meyer A
Rheumatology (Oxford); 2022 Feb; 61(2):756-763. PubMed ID: 33974078
[TBL] [Abstract][Full Text] [Related]
13. Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.
Lilleker JB; Rietveld A; Pye SR; Mariampillai K; Benveniste O; Peeters MT; Miller JA; Hanna MG; Machado PM; Parton MJ; Gheorghe KR; Badrising UA; Lundberg IE; Sacconi S; Herbert MK; McHugh NJ; Lecky BR; Brierley C; Hilton-Jones D; Lamb JA; Roberts ME; Cooper RG; Saris CG; Pruijn GJ; Chinoy H; van Engelen BG;
Ann Rheum Dis; 2017 May; 76(5):862-868. PubMed ID: 28122761
[TBL] [Abstract][Full Text] [Related]
14. Anti-Cytosolic 5'-Nucleotidase 1A Autoantibodies Are Absent in Juvenile Dermatomyositis.
Rietveld A; Wienke J; Visser E; Vree Egberts W; Schlumberger W; van Engelen B; van Royen-Kerkhof A; Lu H; Wedderburn L; Saris C; Tansley S; Pruijn G;
Arthritis Rheumatol; 2021 Jul; 73(7):1329-1333. PubMed ID: 33497020
[TBL] [Abstract][Full Text] [Related]
15. [Sporadic Inclusion Body Myositis and Autoantibodies].
Yamashita S; Ando Y
Brain Nerve; 2018 Apr; 70(4):449-457. PubMed ID: 29632292
[TBL] [Abstract][Full Text] [Related]
16. Testing for serum IgM binding to GM1 ganglioside in clinical practice.
Pestronk A
Neurology; 2000 Jun; 54(12):2353-4. PubMed ID: 10881275
[No Abstract] [Full Text] [Related]
17. Anti-IgLON5 Disease: A New Bulbar-Onset Motor Neuron Mimic Syndrome.
Werner J; Jelcic I; Schwarz EI; Probst-Müller E; Nilsson J; Schwizer B; Bloch KE; Lutterotti A; Jung HH; Schreiner B
Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33531378
[TBL] [Abstract][Full Text] [Related]
18. Pathogenic role of anti-cN1A autoantibodies in sporadic inclusion body myositis.
Yamashita S; Tawara N; Zhang Z; Nakane S; Sugie K; Suzuki N; Nishino I; Aoki M
J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):1018-1024. PubMed ID: 37451693
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of inclusion body myositis.
Greenberg SA
Curr Opin Rheumatol; 2013 Nov; 25(6):753-62. PubMed ID: 24067380
[TBL] [Abstract][Full Text] [Related]
20. Anti-GM1 ganglioside antibodies: their role in the diagnosis and pathogenesis of immune-mediated motor neuropathies.
Kornberg AJ
J Clin Neurosci; 2000 May; 7(3):191-4. PubMed ID: 10833614
[No Abstract] [Full Text] [Related]
[Next] [New Search]
